公开(公告)号：US11944683B2

公开(公告)日：2024-04-02

申请号：US18185477

申请日：2023-03-17

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4196 ,  A61K31/4439 ,  A61K45/06 ,  A61K47/02 ,  A61K47/40 ,  A61K47/69 ,  A61P25/06 ,  C08B37/16

CPC分类号： A61K47/02 ,  A61K9/0053 ,  A61K9/2009 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/40 ,  A61K47/6951 ,  A61P25/06 ,  C08B37/0012 ,  C08B37/0015

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US20240100060A1

公开(公告)日：2024-03-28

申请号：US18510986

申请日：2023-11-16

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61K31/4196 ,  A61P25/06

CPC分类号： A61K31/5415 ,  A61K31/4196 ,  A61P25/06

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US20240091236A1

公开(公告)日：2024-03-21

申请号：US18512551

申请日：2023-11-17

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61K31/415 ,  A61K31/4196 ,  A61K47/02 ,  A61K47/69 ,  A61P25/06

CPC分类号： A61K31/5415 ,  A61K31/415 ,  A61K31/4196 ,  A61K47/02 ,  A61K47/6951 ,  A61P25/06

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam or ibuprofen and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US20240058354A1

公开(公告)日：2024-02-22

申请号：US18489685

申请日：2023-10-18

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61K31/4196 ,  A61P25/06 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/5415 ,  A61K31/4196 ,  A61P25/06 ,  A61K9/205 ,  A61K9/0053 ,  A61K9/2009

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US20230248669A1

公开(公告)日：2023-08-10

申请号：US18300917

申请日：2023-04-14

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/137 ,  A61K9/00

CPC分类号： A61K31/137 ,  A61K9/0053

摘要： This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

公开(公告)号：US20230233574A1

公开(公告)日：2023-07-27

申请号：US18192245

申请日：2023-03-29

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61K31/4196 ,  A61P25/06

CPC分类号： A61K31/5415 ,  A61K31/4196 ,  A61P25/06

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US11660273B2

公开(公告)日：2023-05-30

申请号：US17728554

申请日：2022-04-25

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/137 ,  A61P25/28

CPC分类号： A61K31/137 ,  A61P25/28

摘要： This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

公开(公告)号：US20230131057A1

公开(公告)日：2023-04-27

申请号：US18065013

申请日：2022-12-13

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61P25/06 ,  A61K31/4196

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US11617791B2

公开(公告)日：2023-04-04

申请号：US17656602

申请日：2022-03-25

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/5415 ,  A61K31/4439 ,  A61K47/02 ,  A61K9/00 ,  A61K47/69 ,  A61K47/40 ,  A61K9/20 ,  C08B37/16 ,  A61K45/06

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US11602563B2

公开(公告)日：2023-03-14

申请号：US17837790

申请日：2022-06-10

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K47/02 ,  A61K47/40 ,  A61K45/06 ,  A61K47/69 ,  C08B37/16 ,  A61K31/5415 ,  A61K9/00 ,  A61K31/4439 ,  A61K9/20

摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.